NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No. 135; Pemetrexed for the treatment of malignant pleural mesothelioma

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Eli Lilly (pemetrexed)	Board of Community Health Councils in Wales
Patient/carer groups	 British National Formulary
Afiya Trust	Care Quality Commission
Black Health Agency	 Commissioning Support Appraisals
British Lung Foundation	Service
CANCERactive	 Department of Health, Social Services
Cancer Black Care	and Public Safety for Northern Ireland
Cancer Equality	 Medicines and Healthcare products
 Chinese National Healthy Living 	Regulatory Agency
Centre	 National Association of Primary Care
Counsel and Care	NHS Alliance
Equalities National Council	 NHS Commercial Medicines Unit
 Helen Rollason Heal Cancer Charity 	 NHS Confederation
 Macmillan Cancer Support 	 NHS Quality Improvement Scotland
 Maggie's Centres 	 Public Health Wales NHS Trust
Marie Curie Cancer Care	 Scottish Medicines Consortium
Muslim Council of Britain	
 Muslim Health Network 	Comparator manufacturers
 Roy Castle Lung Cancer Foundation 	Actavis UK (vinorelbine)
South Asian Health FoundationSpecialised Healthcare Alliance	 Bristol-Myers Squibb Pharmaceuticals (cisplatin)
 Sue Ryder Care 	Genus Pharmaceuticals (vinblastine)
Tenovus	Goldshield (cisplatin)
 United Kingdom Lung Cancer 	 Hospira UK (cisplatin, vinblastine,
Coalition	vinorelbine)
Codition	Kyowa Hakko Kirin (mitomycin c)
Professional groups	Medac (venorelbine)
Association of Cancer Physicians	Pfizer (cisplatin)
Association of Respiratory Nurse	Pierre Fabre (vinorelbine)
Specialists	Wockhardt UK (cisplatin, vinorelbine)
British Association for Services to the	

National Institute for Health and Clinical Excellence

Technology Appraisal No. 135; Pemetrexed for the treatment of malignant pleural mesothelioma Issue date: October 2010

Consultees	Commentators (no right to submit or appeal)
 Elderly British Geriatrics Society British Oncological Association British Psychosocial Oncology Society British Thoracic Society Cancer Network Pharmacists Forum Cancer Research UK National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society 	 Relevant research groups British Thoracic Oncology Group Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Institute National Cancer Research Network National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People Assessment Group Assessment Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer
Others Department of Health NHS Camden NHS North Lincolnshire Welsh Assembly Government	Associated Public Health Groups • none

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient

National Institute for Health and Clinical Excellence

Technology Appraisal No. 135; Pemetrexed for the treatment of malignant pleural mesothelioma

Issue date: October 2010

organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supply Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.